(APGE) Apogee Therapeutics, Common - Ratings and Ratios
Cystic Fibrosis,’Atopic Dermatitis,Lung Drugs,Genetic Edits’
Description: APGE Apogee Therapeutics, Common
Apogee Therapeutics, Inc. Common Stock (NASDAQ:APGE) is a biotechnology company listed on the NASDAQ exchange. As a player in the biotechnology industry, APGEs performance is influenced by the sectors overall trends and economic drivers, including government funding for research, patent expirations, and the demand for innovative treatments.
The companys market capitalization stands at approximately $2.4 billion, indicating a significant presence in the market. The absence of a price-to-earnings (P/E) ratio suggests that the company is currently unprofitable, which is not uncommon for biotechnology firms that often invest heavily in research and development (R&D) before generating significant revenue. The return on equity (RoE) of -25.65% further indicates that the company is currently operating at a loss.
Key performance indicators (KPIs) to watch for APGE include R&D expenses as a percentage of revenue, cash burn rate, and the progress of its pipeline assets through clinical trials. The companys ability to secure funding, either through equity issuances, partnerships, or grants, will be crucial in supporting its operations and advancing its product candidates. Economic drivers such as interest rates, investor sentiment towards risk, and the overall health of the biotechnology sector will also impact APGEs stock performance.
To evaluate APGEs potential, its essential to analyze its pipeline, focusing on the therapeutic areas it targets, the stage of development for its lead compounds, and the competitive landscape. The companys financial health, including its cash reserves and ability to manage expenses, will be critical in determining its ability to achieve key milestones and ultimately drive revenue growth. By monitoring these factors, investors can gain a better understanding of APGEs prospects and make more informed investment decisions.
APGE Stock Overview
| Market Cap in USD | 2,257m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2023-07-14 |
APGE Stock Ratings
| Growth Rating | 13.8% |
| Fundamental | 29.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -39.8% |
| Analyst Rating | 5.0 of 5 |
APGE Dividends
Currently no dividends paidAPGE Growth Ratios
| Growth Correlation 3m | -67.3% |
| Growth Correlation 12m | -67.1% |
| Growth Correlation 5y | 36.9% |
| CAGR 5y | 43.02% |
| CAGR/Max DD 3y | 0.73 |
| CAGR/Mean DD 3y | 1.39 |
| Sharpe Ratio 12m | -0.28 |
| Alpha | -37.55 |
| Beta | 0.374 |
| Volatility | 61.60% |
| Current Volume | 494.2k |
| Average Volume 20d | 484.8k |
| Stop Loss | 34.8 (-5.6%) |
| Signal | -0.17 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-237.7m TTM) > 0 and > 6% of Revenue (6% = 7800 TTM) |
| FCFTA -0.26 (>2.0%) and ΔFCFTA -16.84pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.34 (>3.0%) and CFO -220.7m > Net Income -237.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 16.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (58.4m) change vs 12m ago 3.39% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.02% (prev 0.0%; Δ 0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -11.46
| (A) 0.74 = (Total Current Assets 516.1m - Total Current Liabilities 31.6m) / Total Assets 657.8m |
| (B) -0.65 = Retained Earnings (Balance) -427.4m / Total Assets 657.8m |
| (C) -0.37 = EBIT TTM -271.0m / Avg Total Assets 729.2m |
| (D) -11.12 = Book Value of Equity -426.7m / Total Liabilities 38.4m |
| Total Rating: -11.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.11
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -9.78% = -4.89 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda -0.04 = -2.50 |
| 6. ROIC - WACC -42.91% = -12.50 |
| 7. RoE -31.18% = -2.50 |
| 8. Rev. Trend 30.0% = 2.25 |
| 9. EPS Trend 35.01% = 1.75 |
What is the price of APGE shares?
Over the past week, the price has changed by -4.06%, over one month by -1.15%, over three months by -13.49% and over the past year by -28.43%.
Is Apogee Therapeutics, Common a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of APGE is around 31.46 USD . This means that APGE is currently overvalued and has a potential downside of -14.65%.
Is APGE a buy, sell or hold?
- Strong Buy: 9
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the APGE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 97.9 | 165.5% |
| Analysts Target Price | 97.9 | 165.5% |
| ValueRay Target Price | 34.7 | -5.8% |
Last update: 2025-09-09 04:31
APGE Fundamental Data Overview
CCE Cash And Equivalents = 505.4m USD (Cash And Short Term Investments, last quarter)
P/B = 3.6437
Beta = 1.427
Revenue TTM = 130.0k USD
EBIT TTM = -271.0m USD
EBITDA TTM = -270.7m USD
Long Term Debt = 6.82m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 4.03m USD (from shortTermDebt, last quarter)
Debt = 10.8m USD (Calculated: Short Term 4.03m + Long Term 6.82m)
Net Debt = -113.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.76b USD (2.26b + Debt 10.8m - CCE 505.4m)
Interest Coverage Ratio = unknown (Ebit TTM -271.0m / Interest Expense TTM 0.0)
FCF Yield = -9.78% (FCF TTM -172.3m / Enterprise Value 1.76b)
FCF Margin = -132.6k% (FCF TTM -172.3m / Revenue TTM 130.0k)
Net Margin = -182.8k% (Net Income TTM -237.7m / Revenue TTM 130.0k)
Gross Margin = -403.8% ((Revenue TTM 130.0k - Cost of Revenue TTM 655.0k) / Revenue TTM)
Tobins Q-Ratio = -4.13 (set to none) (Enterprise Value 1.76b / Book Value Of Equity -426.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 10.8m)
Taxrate = 21.0% (US default)
NOPAT = -271.0m (EBIT -271.0m, no tax applied on loss)
Current Ratio = 16.36 (Total Current Assets 516.1m / Total Current Liabilities 31.6m)
Debt / Equity = 0.02 (Debt 10.8m / last Quarter total Stockholder Equity 619.4m)
Debt / EBITDA = -0.04 (Net Debt -113.3m / EBITDA -270.7m)
Debt / FCF = -0.06 (Debt 10.8m / FCF TTM -172.3m)
Total Stockholder Equity = 762.2m (last 4 quarters mean)
RoA = -36.13% (Net Income -237.7m, Total Assets 657.8m )
RoE = -31.18% (Net Income TTM -237.7m / Total Stockholder Equity 762.2m)
RoCE = -35.24% (Ebit -271.0m / (Equity 762.2m + L.T.Debt 6.82m))
RoIC = -35.56% (NOPAT -271.0m / Invested Capital 762.2m)
WACC = 7.35% (E(2.26b)/V(2.27b) * Re(7.39%)) + (D(10.8m)/V(2.27b) * Rd(0.0%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 49.35 | Cagr: 1.30%
Discount Rate = 7.39% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -172.3m)
EPS Correlation: 35.01 | EPS CAGR: 32.79% | SUE: -0.72 | # QB: False
Revenue Correlation: 30.0 | Revenue CAGR: 0.0%
Additional Sources for APGE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle